(24/7 MARKET NEWS) – Regulus Therapeutics Inc. (NASDAQ: RGLS) is trading higher, after announcing, this morning, positive topline safety and PK data from its Phase 1 SAD clinical trial of RGLS8429.
At $1.89 and 4.31 million premarket volume, it’s 21 cents higher (+12.50%), but still trading on the low end of its 52-week range of $1.33 to $8.19.
For further details, please go to the Company press release at https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-positive-topline-safety-and-pharmacokinetic-pk-data-from-the-phase-1-single-ascending-dose-sad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-301621359.html.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.